title: Varicella-zoster virus immune status in CAPD and chronic hemodialysis patients.
abstract: Patients on chronic dialysis who are supposed to disclose an impairment of the immune potential, seldom show clinical viral illnesses. Since severe varicella-zoster virus (VZV) infection develops in immunocompromised patients, we have examined the proliferative activity to VZV in the blood lymphocytes of 16 patients on continuous ambulatory peritoneal dialysis (CAPD) and compared it to healthy matched controls. The cellular in vitro response of these patients to specific VZV antigens was essentially normal. The mean stimulation index for CAPD patients was 7.06, and for matched controls 3.68 (p greater than 0.05). The mean percentage of lymphocytes in CAPD patients as determined by CD3 monoclonal antibodies was 57%, the CD4 helper and CD8 suppressor cells were 41 and 21%, respectively. When those 16 CAPD patients were followed up for the presence of anti-VZV IgA, IgM and IgG immunofluorescent antibody to membrane antigen antibodies during a period of 6 months, the recrudescence of VZV was documented by the appearance of IgA and IgM antibodies and/or fourfold increase in IgG titer in some patients, but no clinical illness was observed. The frequent reactivation of the virus without clinical symptoms in patients undergoing long-term intermittent chronic hemodialysis (HD) or CAPD was strengthened by the presence of increased anti-VZV geometric mean titers (52.68 and 53.00, respectively) in these patients as compared to control subjects (11.75).
authors.affiliation: Central Virology Laboratory, Chaim Sheba Medical Center, Holon, Israel.
authors.forename: Z
authors.initials: Z
authors.lastname: Smetana
authors.forename: S
authors.initials: S
authors.lastname: Leventon-Kriss
authors.forename: A
authors.initials: A
authors.lastname: Broide
authors.forename: M
authors.initials: M
authors.lastname: Jedwab
authors.forename: S S
authors.initials: SS
authors.lastname: Smetana
mesh_terms: D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis*; D000956:Antigens, Viral / Q000276:immunology*; D005260:Female; D005455:Fluorescent Antibody Technique; D006562:Herpes Zoster / Q000453:epidemiology / Q000276:immunology*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000628:therapy; D008213:Lymphocyte Activation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis; D016176:T-Lymphocyte Subsets / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral